Drug Trial Radar · NCT03165409
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Last checked: Nov 20, 2026Latest source record: Oct 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,828
Actual
Start
Feb 27, 2017
Primary completion
Sep 30, 2017
Study completion Sep 30, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 24, 2017
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
Conditions
- Melanoma
Interventions
NivolumabBiological
Melanoma intervention
IpilimumabBiological
Melanoma intervention
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visitsTime frame: Approximately 5 years
- Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with more frequent general outpatient visitsTime frame: Approximately 5 years
- Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanomaTime frame: Approximately 5 years
- Treatment-related and all-cause AE costs for nivolumab monotherapy for metastatic melanomaTime frame: Approximately 5 years
- Treatment-related and all-cause AE costs for ipilimumab monotherapy for metastatic melanomaTime frame: Approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bristol-Myers Squibb
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.